Although numerous articles have been written about symptomatic carotid artery stenosis (SCS) and asymptomatic carotid artery stenosis (ACS), many topics remain controversial, among others:
i. the optimal management of patients with ACS, ii. the role of carotid artery stenting (CAS) in ACS and SCS, iii. the relative efficacy of best medical treatment (BMT) versus CAS versus carotid endarterectomy (CEA), and iv. the techniques/options to identify high-risk ACS patients.
This editorial will briefly discuss these controversial issues.
Optimal Management of Patients With ACS
Stroke is the fourth leading cause of death, killing almost 130 000 Americans/year. 1 Every year, more than 795 000 people in the United States have a stroke. 1 About 610 000 of these are first strokes and about 185 000 strokes are in people who had a previous stroke. 1, 2 Approximately 15% are hemorrhagic, while 85% are ischemic. 3 About 20% of the ischemic strokes will affect the vertebrobasilar territory, and 80% will affect the carotid territory. About 50% of the carotid territory ischemic strokes will follow thromboembolism from an extracranial internal carotid artery, while 25% will be due to small vessel intracranial disease (lacunar stroke), 20% will be cardioembolic, and 5% will have miscellaneous/rare etiologies. 3 Accordingly, about 34% of all strokes will be due to thromboembolism arising from the carotid artery bifurcation. However, about two thirds of these patients will have <50% stenosis, leaving approximately 14 for each 100 strokes being due to thromboembolism from a previously 50% to 99% ACS. 3 The benefit of CEA over BMT for significant ACS was established by 3 landmark randomized controlled trials (RCTs), the Asymptomatic Carotid Atherosclerosis Study (60% ACS on ultrasound), 4 the Asymptomatic Carotid Surgery Trial (70% ACS on ultrasound), 5 and the Veterans Affairs Cooperative Study (50% ACS on angiography). 6 These RCTs [4] [5] [6] showed that CEA conferred a 50% relative risk reduction in the 5-year stroke risk (absolute annual stroke risk reduction 1%) compared with BMT. [4] [5] [6] Based on these results, international guidelines recommend that it is reasonable to perform CEA in patients with 70% ACS to reduce the risk of a possible future cerebrovascular event, as long as the perioperative stroke/death rate is <3%. 7, 8 Due to improvements in BMT (eg, routine statin use for patients with carotid atherosclerosis), 9 it was argued that currently the average annual rate of ipsilateral stroke in patients with 50% to 99% ACS receiving BMT alone is much lower than that reported in the historical RCTs. [10] [11] [12] It has been claimed that the '' . . . rates of ipsilateral and any-territory stroke (+ transient ischemic attack [TIA]), with medical intervention alone, have fallen significantly since the mid-1980s, with recent estimates overlapping those of operated patients in randomized trials.'' 10(pe573) The annual ipsilateral stroke rate has been estimated to be 0.5% to 1% per year. [10] [11] [12] As a result, it was argued that individuals with ACS should be managed with BMT alone and that CEA is not justified for these patients. [10] [11] [12] To counter this theory, it is not unusual for patients with ACS to suffer a ''silent'' stroke. A patient suffering a TIA episode in his or her sleep may have no symptoms the following day and thus erroneously continue to be considered as ''asymptomatic.'' In 1998, it was estimated that approximately 770 000 people experienced a symptomatic stroke, while 11 million had an asymptomatic stroke (in other words, a TIA which was missed/went unnoticed). 13 Many of these asymptomatic strokes occurred as a result of ACS. By continuing to consider these patients as asymptomatic (thus managing them with BMT alone [10] [11] [12] and not offering CEA), there is a high risk of recurrent stroke, disability, and/or death. In this context, 43% of major strokes are preceded by a TIA in the previous week. 14 Thus , missing these TIAs and not offering these patients prophylactic CEA may result in a recurrent (and perhaps more severe) neurological event, permanent disability, or death. Another argument is that all patients with carotid stenosis who experience a neurological event were asymptomatic until the day of the event. An even moderate neurologic event, however, may have a considerable and permanent impact on the quality of everyday life of these patients and their relatives/ carers. 15, 16 The optimal management of patients with ACS is therefore a controversial and much debated issue that needs to be addressed in future RCTs. Anne Abbott from Melbourne, Australia, discusses this and other critical issues that need to be addressed to improve outcomes for patients with ACS. 17 The Role of CAS in Patients With ACS and SCS/CAS Versus CEA Versus BMT Carotid artery stenting is a newer and less invasive option than CEA for patients with carotid stenosis. Several RCTs have compared the outcomes of the 2 procedures with conflicting results. [18] [19] [20] [21] To add to this controversy, various societies have reported conflicting recommendations for the management of patients with both ACS and SCS. 7, 8, 22, 23 In contrast to earlier multicenter RCTs, [18] [19] [20] the most recent RCT comparing CAS versus CEA, the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) 21 did not show a significant difference in outcomes between CAS and CEA in patients with both SCS and ACS. However, the equalization of the higher stroke rate after CAS with the higher myocardial infarction rate after CEA cast some doubt on this outcome equivalence. Furthermore, as CREST was launched in 2000, 21 its results do not reflect current practice. Furthermore, neither CAS nor CEA were compared with BMT for patients with ACS. The CREST investigators have therefore launched a second trial to provide answers to these controversial issues. 24 Wesley Moore from University of California, Los Angeles, California, highlights the purpose of CREST-2 and discusses the issues that CREST-2 will hopefully provide answers too. 24 
Identification of High-Risk Individuals With ACS
The identification of ACS individuals at high stroke risk is a field that has attracted considerable attention in the last few years. Although BMT is sufficient for the management of the majority of patients with ACS, some patients with ACS may go on to have a stroke. It is therefore important to identify specific subgroups of patients with ACS who despite BMT are still at increased stroke risk (>2% per year) and may justifiably require a carotid intervention. Identification of these high-risk patients with ACS is crucial to target carotid revascularization procedures appropriately and avoid excessive use of unnecessary interventions. 25 Several methods have been proposed for the identification of patients of ACS at high risk for future stroke, namely: (i) the detection of microemboli by transcranial Doppler, (2) identification of the unstable carotid plaque using ultrasound, (3) reduced cerebral blood flow reserve, (4) intraplaque hemorrhage using magnetic resonance imaging (MRI) scans, (5) silent embolic infarcts on brain computed tomography (CT) or MRI, and (6) progression in the severity of ACS. 26 The role of some of these criteria has been debated, and conflicting reports have been published. 27, 28 The exact prognostic significance of each method should be defined since this could result in improved guidance for the optimal management of patients with ACS.
These and other controversial and critical issues will be discussed in a new special section of Angiology introduced in the current issue of the Journal. Experts from around the world will be invited to discuss/comment on these topics. It is hoped that this special section will attract the interest of readers from all specialties involved in the management of patients with carotid stenosis and will clarify these controversial issues.
